L-Polamidon (Levomethadone Hydrochloride)

Levomethadone Hydrochloride is employed within opioid‑related therapeutic pathways, chiefly for the treatment of opioid dependence and for providing analgesia in chronic pain conditions.

• Opioid dependence: reduces withdrawal symptoms and supports maintenance therapy.
• Chronic pain: provides analgesic relief for moderate to severe persistent pain.
• Detoxification: assists in supervised opioid detox programs to ease transition off opioids.

• Levomethadone acts as a potent agonist at the µ‑opioid receptors in the central nervous system, mimicking the effects of endogenous endorphins. By binding to these G‑protein‑coupled receptors, it inhibits adenylate cyclase activity, reduces neuronal excitability, and decreases the release of neurotransmitters involved in pain transmission and reward pathways. Its high affinity and intrinsic activity produce strong analgesic and anti‑withdrawal effects while also modulating respiratory drive.

Levomethadone may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects

• Nausea
• Constipation
• Dizziness
• Sedation

Serious or Rare Side Effects

• Respiratory depression
• QT interval prolongation
• Seizures
• Severe allergic reactions

When prescribing levomethadone, clinicians should observe several safety precautions to minimize risk.

• Respiratory assessment: evaluate baseline breathing function and monitor for depression.
• Cardiac monitoring: check QT interval and avoid use in patients with known prolongation.
• Hepatic function: adjust dose or avoid in severe liver impairment.
• Concomitant CNS depressants: use caution when combined with alcohol, benzodiazepines, or other opioids.
• Discontinuation: taper gradually under medical supervision to prevent withdrawal.
• Store at below 25°C: keep in original packaging, protect from moisture and light.

Levomethadone interacts with several drug classes; awareness of these interactions helps prevent adverse events.

Major Interactions (Avoid)

• Other opioids: additive respiratory depression.
• CNS depressants (e.g., benzodiazepines, barbiturates): heightened sedation and respiratory risk.
• MAO inhibitors: risk of severe hypertension or serotonin syndrome.
• QT‑prolonging agents (e.g., certain antiarrhythmics, antipsychotics): increased cardiac arrhythmia risk.

Moderate Interactions (Monitor Closely)

• CYP3A4 inhibitors (e.g., erythromycin, ketoconazole): may raise levomethadone levels.
• Alcohol: enhances sedative effects.
• Antidepressants (especially SSRIs): potential for increased sedation.
• Antihistamines: may augment drowsiness.